Showing 1416 results
-
Press release /Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases IgA nephropathy (IgAN), while rare, is the most common form of…
-
Press release /Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
-
Ad hoc release /Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
-
Press release /First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…
-
Press release /Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
-
Press release /AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
-
Press release /Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
-
Press release /Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon…
-
Press release /Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
-
Press release /Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…